January 11, 2023 04:45 PM ESTUpdated January 15, 11:12 PM
R&D
Pharma

Ex­perts talk IRA im­pacts as CMS an­nounces it will pub­lish first 10 drugs up for ne­go­ti­a­tion in Sep­tem­ber

Lei Lei Wu

News Reporter

Ex­perts went back and forth on the im­pacts of the In­fla­tion Re­duc­tion Act, or IRA, on the bio­phar­ma in­dus­try in a vir­tu­al pan­el host­ed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times